Literature DB >> 15897036

Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report.

M Lissia1, A Figus, C Rubino.   

Abstract

Toxic epidermal necrolysis (TEN) is an acute drug-induced life-threatening disorder characterised by extensive epidermal exfoliation and high rate of mortality. Between October 2000 and April 2003, five severe TEN patients were evaluated using a specific TEN severity-of-illness scale (SCORTEN) and treated for the first time, with a combined therapy using Intravenous Human Immunoglobulins (IVIG) and plasmapheresis. The standardised mortality ratio (SMR) analysis ([Sigma observed deaths/Sigma expected deaths]x100) was applied to establish how IVIG and plasmapheresis treatment could reduce TEN patient mortality. The observed mortality was one out of five patients corresponding to 20%. The expected mortality based on SCORTEN was 3.319 corresponding to 66%. The SMR analysis revealed a 70% reduction in mortality (SMR=0.30; 95% confidence interval, 0.0-0.96). Our series show a low mortality rate (20%) related to the severity of the patients (66% expected mortality). The use of IVIG in association with plasmapheresis has a rational basis and may be effective in severe TEN patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15897036     DOI: 10.1016/j.bjps.2004.12.007

Source DB:  PubMed          Journal:  Br J Plast Surg        ISSN: 0007-1226


  11 in total

1.  Antecedent Drug Exposure Aetiology and Management Protocols in Steven-Johnson Syndrome and Toxic Epidermal Necrolysis, A Hospital Based Prospective Study.

Authors:  Samina Farhat; Muddasir Banday; Iffat Hassan
Journal:  J Clin Diagn Res       Date:  2016-01-01

2.  Review of intravenous immunoglobulin in the treatment of stevens-johnson syndrome and toxic epidermal necrolysis.

Authors:  Saira B Momin
Journal:  J Clin Aesthet Dermatol       Date:  2009-02

3.  New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited.

Authors:  Philippe Paquet; Gérald E Piérard
Journal:  Drug Saf       Date:  2010-03-01       Impact factor: 5.606

4.  Immunoglobulin injection for the treatment of multiple oral ulcers in Stevens-Johnson syndrome.

Authors:  M Cicciù; F Chiera; R Gallizzi; A Cicciù; C D Salpietro
Journal:  Eur Arch Paediatr Dent       Date:  2013-10-01

Review 5.  Toxic epidermal necrolysis and Stevens-Johnson syndrome.

Authors:  Thomas Harr; Lars E French
Journal:  Orphanet J Rare Dis       Date:  2010-12-16       Impact factor: 4.123

6.  The Effect of Intravenous Immunoglobulin Combined with Corticosteroid on the Progression of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Meta-Analysis.

Authors:  Liang-Ping Ye; Cheng Zhang; Qi-Xing Zhu
Journal:  PLoS One       Date:  2016-11-30       Impact factor: 3.240

Review 7.  Treatments for Severe Cutaneous Adverse Reactions.

Authors:  Yung-Tsu Cho; Chia-Yu Chu
Journal:  J Immunol Res       Date:  2017-12-27       Impact factor: 4.818

8.  Lyell's Syndrome and Antimalarials: A Case Report and Clinical Review.

Authors:  Joana Miranda Nunes; Sofia Santareno; Lina Guerreiro; Ana Filipa Margalho
Journal:  J Glob Infect Dis       Date:  2017 Jan-Mar

Review 9.  Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Akito Hasegawa; Riichiro Abe
Journal:  F1000Res       Date:  2020-06-16

Review 10.  Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

Authors:  Sheena N Ramasamy; Cameron S Korb-Wells; Diluk R W Kannangara; Myles W H Smith; Nan Wang; Darren M Roberts; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.